Amarin reported 86.89M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Aerie Pharmaceuticals AERI:US $ 28.15M 3.38M
Alnylam Pharmaceuticals ALNY:US $ 169.98M 15.51M
Amarin AMRN:US 86.89M 3.75M
AstraZeneca AZN:LN 3.27B 209M
Biocryst Pharmaceuticals BCRX:US $ 38.02M 3.74M
Epizyme EPZM:US $ 27.2M 3.66M
Esperion Therapeutics ESPR:US $ 29.61M 772K
GlaxoSmithKline GSK:LN 1.96B 726M
Halozyme Therapeutics HALO:US $ 13.83M 60K
Heron Therapeutics HRTX:US $ 32.96M 1.42M
Intercept Pharmaceuticals ICPT:US $ 39.98M 10.02M
JAZZ PHA JAZZ:US 325.67M 16.86M
Nektar Therapeutics NKTR:US $ 21.44M 5.9M
Neurocrine Biosciences NBIX:US $ 182.8M 17.9M
Novartis NOVN:VX 3.59B 91M
Teva Pharmaceutical Industries TEVA:US 849M 30M